Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurobiol Aging. 2011 Dec;32 Suppl 1:S48-57. doi: 10.1016/j.neurobiolaging.2011.09.011.

Alliance for aging research AD biomarkers work group: structural MRI.

Author information

  • Mayo Foundation, Rochester, MN 55905, USA. jack.clifford@mayo.edu

Abstract

Biomarkers of Alzheimer's disease (AD) are increasingly important. All modern AD therapeutic trials employ AD biomarkers in some capacity. In addition, AD biomarkers are an essential component of recently updated diagnostic criteria for AD from the National Institute on Aging--Alzheimer's Association. Biomarkers serve as proxies for specific pathophysiological features of disease. The 5 most well established AD biomarkers include both brain imaging and cerebrospinal fluid (CSF) measures--cerebrospinal fluid Abeta and tau, amyloid positron emission tomography (PET), fluorodeoxyglucose (FDG) positron emission tomography, and structural magnetic resonance imaging (MRI). This article reviews evidence supporting the position that MRI is a biomarker of neurodegenerative atrophy. Topics covered include methods of extracting quantitative and semiquantitative information from structural MRI; imaging-autopsy correlation; and evidence supporting diagnostic and prognostic value of MRI measures. Finally, the place of MRI in a hypothetical model of temporal ordering of AD biomarkers is reviewed.

Copyright © 2011. Published by Elsevier Inc.

PMID:
22078173
[PubMed - indexed for MEDLINE]
PMCID:
PMC3661287
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk